Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Wei Zhao
1,500 participants
Jan 31, 2016
INTERVENTIONAL
Conditions
Summary
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.
Eligibility
Inclusion Criteria2
- Patients must be diagnosed with hematological neoplasms
- Antineoplastic drugs or anti-infective drugs used as part of regular treatment
Exclusion Criteria2
- expected survival time less than the treatment cycle;
- patients with other factors that researcher considers unsuitable for inclusion.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
bortezomib was administered follow the doctor's advice.
eltrombopag was administered follow the doctor's advice.
imatinib was administered follow the doctor's advice.
dasatinib was administered follow the doctor's advice.
pegaspargase was administered follow the doctor's advice.
anti-infective drugs was administered follow the doctor's advice.
pegaspargase was administered follow the doctor's advice.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03844360